# AmacaThera

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/amacathera

- Industry: Materials
- Headquarters: Toronto, Canada
- Website: www.amacathera.ca
- Total disclosed funding: $41M
- Latest round: Series A (Nov 28, 2023)
- Investors on record: 11

## About

Based in Toronto, Canada, AmacaThera Inc. is a biotechnology company specializing in advanced sustained release hydrogel formulations aimed at improving drug delivery and patient outcomes in various therapeutic areas.AmacaThera Inc. focuses on innovative drug delivery systems, specifically through its flagship AmacaGel platform. Founded in 2016 in Toronto, Canada, by Mike Cooke, the company has successfully completed four funding rounds, with the latest, a Series A, raising CAD 40.0 million on November 28, 2023, from investors including BDC Capital, Inveready Asset Management, and others.AmacaThera Inc. specializes in advanced sustained release hydrogel formulations, with its core product being the AmacaGel delivery platform. This injectable hydrogel technology enables localized and sustained drug delivery to enhance patient outcomes, particularly in post-surgical pain management and cancer treatment. The flagship product, AMT-143, is designed for non-opioid acute pain management and has recently undergone clinical trials. The primary customers include healthcare providers, hospitals, and clinics serving patients in Canada and the United States.AmacaThera’s revenue model is built on partnerships with healthcare providers and institutions that utilize its therapeutic products. The company has recently secured CAD 4.0 million in funding to further advance its clinical development. Their operations typically involve agreements with hospitals and clinics to integrate the AmacaGel platform into pain management protocols. While specific pricing details are not disclosed, the company operates a business-to-business framework, focusing on the procurement of its injectable hydrogel formulations for clinical use.In November 2023, AmacaThera Inc. raised CAD 40 million in Series A funding, which will be directed towards expanding and accelerating its clinical development of injectable products. The company aims to launch new products to enhance their therapeutic offerings and plans to explore market expansion into new geographic regions. By utilizing the recent funding, AmacaThera intends to bolster its clinical trials and engage more healthcare facilities to integrate its innovative drug delivery technologies.

## Funding rounds

- Series A, Nov 28, 2023, $30M — BDC Capital, Inveready Asset Management, MaRS Investment Accelerator Fund, StandUp Ventures, Lumira Ventures
- Series A, Feb 22, 2021, $8.2M — BDC Capital, Inveready Asset Management, CR Capital, MaRS Investment Accelerator Fund, StandUp Ventures, Sprout BioVentures, MBX Capital, Viva BioInnovator, Lumira Ventures
- Seed, Oct 3, 2019, $0.3M — Lumira Ventures
- Seed, Jan 8, 2019, $2.4M — Grey Sky Venture Partners, Sprout BioVentures, Viva Biotech Holdings

## Investors

- Grey Sky Venture Partners (https://capitalatlas.ai/funds/grey-sky-venture-partners) — Seed
- Sprout BioVentures (https://capitalatlas.ai/funds/sprout-bioventures) — Seed, Series A
- Viva Biotech Holdings — Seed
- Lumira Ventures (https://capitalatlas.ai/funds/lumira-ventures) — Seed, Series A
- BDC Capital (https://capitalatlas.ai/funds/bdc-capital) — Series A
- Inveready Asset Management (https://capitalatlas.ai/funds/inveready-asset-management) — Series A
- CR Capital (https://capitalatlas.ai/funds/cr-capital) — Series A
- MaRS Investment Accelerator Fund (https://capitalatlas.ai/funds/mars-investment-accelerator-fund) — Series A
- StandUp Ventures (https://capitalatlas.ai/funds/standup-ventures) — Series A
- MBX Capital (https://capitalatlas.ai/funds/mbx-capital) — Series A
- Viva BioInnovator (https://capitalatlas.ai/funds/viva-bioinnovator) — Series A